Careers in Israel
Careers in the US
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
pioneer in computational drug target discovery
Innovative immuno-oncology pipeline
Jan 09, 2020
Compugen Highlights Recent Accomplishments and Previews Upcoming Milestones
Jan 08, 2020
Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE®(video)
COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.
BAY 1905254/ILDR2 (partnered)
ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.
COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.
COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701
Multiple myeloid programs
Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.
Feb 06, 2020
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, The ASCO-SITC Clinical Immuno-Oncology Symposium
Nov 11, 2019
Compugen Third Quarter 2019 Conference Call
Nov 09, 2019
COM902, a Novel Therapeutic Antibody Targeting TIGIT Augments T Cell Function and the Activity of PVRIG Pathway Blockade In Vitro and In Vivo” (Poster no. P322)
Click here for more info about partnering with Compugen